Exhibit 10.14
First Amendment to
ONCOSIGNATURE COMPANION DIAGNOSTIC Agreement
This First Amendment to Oncosignature Companion Diagnostic Agreement (the “First Amendment”) is made and entered into as of December 21, 2022 (the “First Amendment Effective Date”) by and between:
Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at 480 Arsenal Way, Suite 100, Watertown, MA 02472 (“Acrivon”), and
Akoya Biosciences, Inc., a Delaware corporation with its principal place of business at 100 Campus Drive, 6th floor, Marlborough, MA 01752 (“Akoya”).
Acrivon and Akoya are each referred to individually as a “Party” and together as the “Parties.”
Whereas, Acrivon and Akoya are parties to that certain Oncosignature Companion Diagnostic Agreement, dated June 17, 2022 (the “Agreement”), under which the Parties are collaborating to develop, validate, obtain regulatory approval for, and commercialize a companion diagnostic test for use with Prexasertib; and
Whereas, the Parties now wish to amend certain terms of the Agreement, as set forth in more detail below.
Now therefore, in consideration of the mutual promises and agreement set forth herein, and for other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
[Signature Page Follows]
In Witness Whereof, the Parties have executed this First Amendment in duplicate originals by their proper officers as of the First Amendment Effective Date.
Acrivon Therapeutics, Inc.
Name: Peter Blume-Jensen Title: Chief Executive Officer | Akoya Biosciences, Inc.
Name: Brian McKelligon Title: Chief Executive Officer |
Exhibit A
Schedule 3.5
Development Milestones; Development Milestone Payments
[***]